Skip over navigation
Banner
Industry
Directory Facilities Technology Transfer Economic Develop. KS BioHistory (TM)
Career
Job Search Post a Job Submit Resume Destination KS
News/Events
Local KS News Submit News Release Calendar Submit Event CEO Reading
Patient
Clinical Trials Local Support National Resources
Education
K-12 Higher Ed BioEd Reading
About
Board Advertising Feedback Home
 
News
 Local KS News
 Submit News Release
 Calendar
 Submit Event
 CEO Reading
Quick Links
 Directory
 Job Search
 Facilities
 Calendar
 Advertising
Community Service Ad:  Every Child Deserves a Chance to Play Baseball
Events
 
Facilities
 

ATC clean room constructors...validation guaranteed!


Medchem Source

Local News

Submit News Release


Search Articles: 

  • Spectranetics announces Federal investigation  Spectranetics was jointly served by the Food and Drug Administration (FDA) and U.S. Immigration and Customs Enforcement (ICE) this morning with a search warrant issued by the United States District Court, District of Colorado.
    Spectranetics Corporation September 04, 2008  
  • Abbott recognized on Dow Jones Sustainability Index (DJSI) for fourth consecutive year  Abbott announced that it was recognized on the Dow Jones Sustainability World Index and the Dow Jones Sustainability North America Index for the fourth consecutive year.
    Abbott September 04, 2008  
  • Amgen and Wyeth statement on the FDA Safety Announcement regarding TNF blockers  Amgen and Wyeth Pharmaceuticals issued a statement in response to the Food and Drug Administration (FDA) safety announcement regarding opportunistic fungal infections in patients treated with Tumor Necrosis Factor (TNF) blockers (marketed as Remicade(R), Enbrel(R), Humira(R) and Cimzia(R)).
    Amgen September 04, 2008  
  • Percutaneous coronary intervention with CYPHER(R) stent comparable to bypass surgery  Data from the largest randomized trial of its kind performed to date indicate that the use of percutaneous coronary intervention with the CYPHER(R) Sirolimus-eluting Coronary Stent was comparable to bypass surgery in key safety endpoints in patients with multi-vessel disease and diabetes.
    Johnson & Johnson September 04, 2008  
  • Monsanto's Roundup Ready 2 Yield(TM) Soybeans receive China regulatory approval  Monsanto Company announced it has received regulatory approval in China for the importation of Roundup Ready 2 Yield(TM) soybeans. China imports accounted for approximately 38 percent of U.S. soybean exports in 2007, making it the largest purchaser of U.S. soybeans.
    Monsanto Company September 04, 2008  
  • ViroPharma and Lev receive Hart-Scott-Rodino Clearance from FTC  ViroPharma and Lev Pharmaceuticals announced that the waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act has expired in connection with ViroPharma's proposed acquisition of Lev Pharmaceuticals.
    ViroPharma Inc. September 03, 2008  
  • Pfizer and Medivation enter into global agreement to co-develop and market Dimebon  Pfizer and Medivation have entered into an agreement to develop and commercialize Dimebon, Medivation's investigational drug for Alzheimer's disease and Huntington's disease. Dimebon currently is being evaluated in an international, confirmatory Phase III trial.
    Pfizer Inc September 03, 2008  
  • Gates Foundation accepting proposals for Grand Challenges Explorations Round 2  The Bill & Melinda Gates Foundation announced that it is now accepting grant proposals for Round 2 of Grand Challenges Explorations, a five-year US$100 million initiative to encourage bold and unconventional research on new global health solutions. Proposals will be accepted through November 2.
    The Bill & Melinda Gates Foundation September 03, 2008  
  • Wyeth names Daniel J. McIntyre vice president, corporate communications  Wyeth announced the appointment of Daniel McIntyre to VP, Corporate Communications. Mr. McIntyre will be responsible for all internal and external communications for the corporation and its three major divisions -- pharmaceuticals, consumer health care and animal health -- around the world.
    Wyeth September 03, 2008  
  • Adenosine Therapeutics to be acquired by Clinical Data  Clinical Data announced that it has entered into an agreement to acquire Adenosine Therapeutics. Clinical Data paid $11 million in cash, and entered into a $22 million, five-year promissory note and a separate $3.2 million, 32-month promissory note to acquire the privately held Adenosine.
    Clinical Data, Inc. September 03, 2008  

   (next 10 articles)

Search Articles: 


Submit News Release

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page

© 2008 Info.Resource, Inc. All rights reserved.
Privacy Policy . Terms of Use . Advisory Board . Advertising

KansasLifeScience.com, owned and published by Info.Resource, Inc., is a resource
for the life science industry in the state of Kansas.